- Puma Biotechnology (NASDAQ:PBYI) is getting roughed up premarket. Shares are down 25% on robust volume in apparent response to Roche's announcement of positive late-stage study results showing the benefit of Perjeta (pertuzumab) in HER2-positive breast cancer.
- Puma's candidate for HER2+ breast cancer is neratinib (PB272), currently under review at the FDA.
- Previously: FDA accepts Puma Bio's NDA for lead product candidate neratinib for breast cancer; shares up 7% premarket (Sept. 20, 2016)
- Previously: Roche's Perjeta helps women with aggressive type of breast cancer live longer without cancer returning compared to Herceptin + chemo (March 2)
Puma Bio sinks after Roche announces positive Perjeta data in HER2+ breast cancer; shares off 25% premarket
Recommended For You
About PBYI Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| PBYI | - | - |
| Puma Biotechnology, Inc. | ||